Symtuza

DRUG5 trials

Sponsors

NEAT ID Foundation, ADRIANO LAZZARIN, MD, Midland Research Group, Inc., Chelsea and Westminster NHS Foundation Trust, East Carolina University

Conditions

HIV InfectionsHIV-1-infectionHIV/AIDSHuman Immunodeficiency VirusObesity

Phase 3

The Late Presenter Treatment Optimisation Study

CompletedNCT03696160

NEAT ID FoundationHIV/AIDS

Start: 2019-03-05End: 2024-06-17Updated: 2025-12-17

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

CompletedNCT04653194

Chelsea and Westminster NHS Foundation TrustHuman Immunodeficiency Virus

Start: 2020-09-30End: 2023-07-31Updated: 2024-02-08

Phase 4

Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).

ADRIANO LAZZARIN, MDHIV-1-infection

Start: 2018-05-07End: 2021-06-14Target: 112Updated: 2020-01-13

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

TerminatedNCT04240210

Midland Research Group, Inc.Human Immunodeficiency Virus

Start: 2019-09-17End: 2021-12-01Updated: 2024-09-19

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

East Carolina UniversityHIV Infections, Obesity

Start: 2023-03-14End: 2025-03-31Target: 30Updated: 2023-11-14

Related Papers

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.

2025-12-01

Evaluation of the effect of 48 weeks of BIC/F/TAF and DRV/c/F/TAF on platelet function in the context of rapid ART start

HIV Research & Clinical Practice2025-01-07

HIV‐DNA decrease during treatment in primary HIV‐1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial

Journal of Medical Virology2023-09-019 citations